Active substance Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor
Holder Parexel International on behalf of Vertex Pharmaceuticals Incorporated
Status Running
Indication for Patients 2 Through 5 Years of Age With Cystic Fibrosis Who Have At Least One F508del Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene
Public documents Approbation
  Information for the patient
  Informed consent
Last update 18/09/2023


Last updated on 18/09/2023